Abstract
To investigate the occurrence of vascular comorbidities before and after the clinical onset of multiple sclerosis. In this combined case–control and cohort study, all Danish born citizens with onset of multiple sclerosis 1980–2005 were identified from the Danish Multiple Sclerosis Registry and randomly matched with controls regarding year of birth, gender, and municipality on January 1st in the year of multiple sclerosis (MS) onset (index date). Individual-level information on comorbidities was obtained from several independent nationwide registries and linked to the study population by unique personal identification numbers. To assess the presence of vascular comorbidities before and after MS onset, cases and controls were followed from January 1977 to the index date, and from the index date through December 2012. We used logistic regression to calculate odds ratios (ORs) and Cox regression to calculate hazard ratios (HRs). Before the index date, MS cases had a decreased probability for cerebrovascular comorbidity [OR 0.69 (95 % CI 0.48–0.99, p = 0.043)], and a numerically but not statistically significant decreased probability for cardiovascular comorbidity [OR 0.87 (95 % CI 0.71–1.07, p = 0.188)]. After the index date, MS cases had an increased risk for cerebrovascular comorbidity [HR 1.84 (95 % CI 1.69–2.00, p < 0.0005)], and for cardiovascular comorbidity [HR 1.08 (95 % CI 1.02–1.15, p = 0.013)]. The lower occurrence of cerebrovascular comorbidities in cases prior to MS onset could be due to protective immune mechanisms, while the higher occurrence of vascular comorbidities in cases after MS onset could be because of converging causal pathways of the coexisting diseases. These findings deserve to be studied closer in a broader spectrum of comorbidities in MS.
Similar content being viewed by others
References
Feinstein AR (1970) The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis 23(7):455–468
Marrie RA, Miller A, Sormani MP, Thompson A, Waubant E, Trojano M, O’Connor P, Fiest K, Reider N, Reingold S, Cohen J (2016) Recommendations for observational studies of comorbidity in multiple sclerosis. Neurology 86(15):1446–1453. doi:10.1212/WNL.0000000000002474
Marrie RA, Miller A, Sormani MP, Thompson A, Waubant E, Trojano M, O’Connor P, Reingold S, Cohen JA (2016) The challenge of comorbidity in clinical trials for multiple sclerosis. Neurology 86(15):1437–1445. doi:10.1212/WNL.0000000000002471
Koch-Henriksen N, Magyari M, Laursen B (2015) Registers of multiple sclerosis in Denmark. Acta Neurol Scand Suppl 132(199):4–10. doi:10.1111/ane.12424
Schmidt M, Pedersen L, Sorensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29(8):541–549. doi:10.1007/s10654-014-9930-3
Koch-Henriksen N, Rasmussen S, Stenager E, Madsen M (2001) The Danish Multiple Sclerosis Registry. History, data collection and validity. Dan Med Bull 48(2):91–94
Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public Health 39(7 Suppl):30–33. doi:10.1177/1403494811401482
Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT (2011) The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 11:83. doi:10.1186/1471-2288-11-83
Kildemoes HW, Sorensen HT, Hallas J (2011) The Danish National Prescription Registry. Scand J Public Health 39(7 Suppl):38–41. doi:10.1177/1403494810394717
Helweg-Larsen K (2011) The Danish Register of causes of death. Scand J Public Health 39(7 Suppl):26–29. doi:10.1177/1403494811399958
Erlangsen A, Fedyszyn I (2015) Danish nationwide registers for public health and health-related research. Scand J Public Health 43(4):333–339. doi:10.1177/1403494815575193
Motl RW, McAuley E, Snook EM (2005) Physical activity and multiple sclerosis: a meta-analysis. Mult Scler 11(4):459–463
Ranadive SM, Yan H, Weikert M, Lane AD, Linden MS, Baynard T, Motl RW, Fernhall B (2012) Vascular dysfunction and physical activity in multiple sclerosis. Med Sci Sports Exerc 44(2):238–243. doi:10.1249/MSS.0b013e31822d7997
Manouchehrinia A, Tench CR, Maxted J, Bibani RH, Britton J, Constantinescu CS (2013) Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain 136(Pt 7):2298–2304. doi:10.1093/brain/awt139
Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T (2009) High frequency of adverse health behaviors in multiple sclerosis. Mult Scler 15(1):105–113. doi:10.1177/1352458508096680
Khurana SR, Bamer AM, Turner AP, Wadhwani RV, Bowen JD, Leipertz SL, Haselkorn JK (2009) The prevalence of overweight and obesity in veterans with multiple sclerosis. Am J Phys Med Rehabil 88(2):83–91. doi:10.1097/PHM.0b013e318194f8b5
Crowson CS, Nicola PJ, Kremers HM, O’Fallon WM, Therneau TM, Jacobsen SJ, Roger VL, Ballman KV, Gabriel SE (2005) How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum 52(10):3039–3044
Gefland JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296(14):1735–1741
Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB (2008) C-reactive protein and coronary heart disease: a critical review. J Intern Med 264(4):295–314. doi:10.1111/j.1365-2796.2008.02015.x
Kushner I, Elyan M (2008) Why does C-reactive protein predict coronary events? Am J Med 121(7):e11. doi:10.1016/j.amjmed.2008.03.004
Christiansen CF, Christensen S, Farkas DK, Miret M, Sorensen HT, Pedersen L (2010) Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology 35(4):267–274. doi:10.1159/000320245
Jadidi E, Mohammadi M, Moradi T (2013) High risk of cardiovascular diseases after diagnosis of multiple sclerosis. Mult Scler 19(10):1336–1340. doi:10.1177/1352458513475833
Roshanisefat H, Bahmanyar S, Hillert J, Olsson T, Montgomery S (2014) Multiple sclerosis clinical course and cardiovascular disease risk—Swedish cohort study. Eur J Neurol 21(11):1353–1360. doi:10.1111/ene.12518
Kang JH, Chen YH, Lin HC (2010) Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur J Neurol 17(9):1215–1219. doi:10.1111/j.1468-1331.2010.02971
Allen NB, Lichtman JH, Cohen HW, Fang J, Brass LM, Aldeman MH (2008) Vascular disease among hospitalized MS patients. Neuroepidemiology 30(4):234–238. doi:10.1159/000128103
Lavela SL, Prohaska TR, Furner S, Weaver FM (2012) Chronic diseases in male veterans with multiple sclerosis. Prev Chronic Dis 9:E55
Fleming ST, Blade RL Jr (1994) Patterns of comorbidity in elderly patients with multiple sclerosis. J Clin Epidemiol 47(10):1127–1132
Marrie RA, Yu BN, Leung S, Elliott L, Caetano P, Warren S, Wolfson C, Patten SB, Svenson LW, Tremlett H, Fisk J, Blanchard JF (2013) Prevalence and incidence of ischemic heart disease in multiple sclerosis: a population-based validation study. Mult Scler Relat Disord 2(4):355–361. doi:10.1016/j.msard.2013.03.001
Marrie RA, Fisk J, Tremlett H, Wolfson C, Warren S, Blanchard J, Patten SB (2016) Differing trends in the incidence of vascular comorbidity in MS and the general population. Neurol Clin Pract 6(2):120–128
Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, Reingold S, Sorensen PS (2015) A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Mult Scler 21(3):282–293
D’Haeseleer M, Cambron M, Vanopdenbosch L, De Keyser J (2011) Vascular aspects of multiple sclerosis. Lancet Neurol 10(7):657–666. doi:10.1016/S1474-4422(11)70105-3
Munger KL, Bentzen J, Laursen B, Stenager E, Koch-Henriksen N, Sorensen TI, Baker JL (2013) Childhood body mass index and multiple sclerosis risk: a long-term cohort study. Mult Scler 19(10):1323–1329. doi:10.1177/1352458513483889
Freedman DS, Patel DA, Srinivasan SR, Chen W, Tang R, Bond MG, Berenson GS (2008) The contribution of childhood obesity to adult carotid intima-media thickness: the Bogalusa heart study. Int J Obes (Lond) 32(5):749–756. doi:10.1038/sj.ijo.0803798
Hedstrom AK, Olsson T, Alfredsson L (2016) Smoking is a major preventable risk factor for multiple sclerosis. Mult Scler 22(8):1021–1026
Rose G (1973) Smoking and cardiovascular disease. Am Heart J 85(6):838–840
Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A (2006) Serum 25-hydroxy vitamin D levels and risk of multiple sclerosis. JAMA 296(23):2832–2838
Anderson JL, May HT, Horne BD, Bair TL, Hall NL, Carlquist JF, Lappe DL, Muhlestein JB (2010) Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 106(7):963–968. doi:10.1016/j.amjcard.2010.05.027
Thacker EL, Mirzaei F, Ascherio A (2006) Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 59(3):499–503
de Boer OJ, Teeling P, Idu MM, Becker AE, van der Wal AC (2006) Epstein Barr virus specific T-cells generated from unstable human atherosclerotic lesions: implications for plaque inflammation. Atherosclerosis 184(2):322–329
Koch MW, Metz LM, Kovalchuk O (2013) Epigenetic changes in patients with multiple sclerosis. Nat Rev Neurol 9(1):35–43. doi:10.1038/nrneurol.2012.226
Murray TJ (2006) The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks? Expert Opin Drug Saf 5(2):265–274
Paolicelli D, Manni A, Direnzo V, D’Onghia M, Tortorella C, Zoccolella S, Trojano M (2015) Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: a postmarketing study. J Clin Pharmacol 55(10):1131–1136. doi:10.1002/jcph.519
Wei L, MacDonald TM, Walker BR (2004) Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 141(10):764–770
Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Sogaard LV, Olsen IC, Sandberg-Wollheim M (2009) NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol 8(6):519–529. doi:10.1016/S1474-4422(09)70085-7
Ravnborg M, Sorensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholome E, Constantinescu CS, Beer K, Garde E, Sperling B (2010) Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol 9(7):672–680. doi:10.1016/S1474-4422(10)70132-0
Schacke H, Docke WD, Asadullah K (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96(1):23–43
Acknowledgments
This study was funded by the Danish Multiple Sclerosis Society.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None.
Ethical standard
The manuscript does not contain clinical studies or patient data. The identity of persons in this study was encrypted, before the investigators gained access to data. Permission to process data was granted by The Danish Data Protection Agency; Capital Region ID 02,859, local number 30-1218.
Rights and permissions
About this article
Cite this article
Thormann, A., Magyari, M., Koch-Henriksen, N. et al. Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark. J Neurol 263, 2484–2493 (2016). https://doi.org/10.1007/s00415-016-8295-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-016-8295-9